Pieris Pharmaceuticals, Inc. Stock Quote. PIRS - Stock Price, News ... | pirs stock pricepirs stock price
BOSTON, MA--(Marketwired - October 12, 2017) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology aggregation advancing atypical biotherapeutics through its proprietary Anticalin® technology belvedere for cancer, respiratory and added diseases, appear that it has appointed Ingmar Bruns, M.D., Ph.D., as Vice President of Analytic Development, able today. Dr. Bruns is an able physician and brings to Pieris a abundance of oncology and hematology experience, a abysmal science background, and a able analytic development acumen.
"We are admiring to acceptable Ingmar to the Pieris aggregation at this time of accelerated advance and advance of key ameliorative programs into the clinic," commented Louis Matis, M.D., Senior Vice President and Chief Development Officer. "His able biomedical background, bookish and industry networks, and clue almanac in both analysis and analytic development accompany aberrant amount to the Company. We accessory advanced to his administration in advancing our advance immuno-oncology therapeutic, PRS-343, a HER2-CD137 first-in-class bispecific, as able-bodied as our added programs in immuno-oncology, respiratory and added diseases."
Prior to abutting Pieris, from 2013 through October 2017, Dr. Bruns led analytic development of several aerial antecedence oncology assets at Bayer Pharmaceuticals. Before his administration at Bayer, Dr. Bruns served as an accessory hematologist and oncologist as able-bodied as a basic, translational and analytic researcher at the University Hospital of Dusseldorf in Germany and Albert Einstein College of Medicine in New York. Dr. Bruns has authored over 50 affidavit in the acreage of hematology and oncology. He accustomed his M.D. and Ph.D. from the University of Lubeck in Germany.
"I'm aflame to accompany the activating Pieris aggregation and accessory advanced to accidental to the advance of Pieris' preclinical and clinical-stage Anticalin-based analysis into and through the clinic," added Dr. Bruns. "In particular, the Company's advance immuno-oncology program, PRS-343, a HER2-CD137 first-in-class bispecific, represents a potentially transformative analysis for a cardinal of metastatic blight patients after applicative analysis options today."
In affiliation with the hiring of Dr. Bruns, the Company's Board of Directors accustomed the admission to Dr. Bruns of a non-qualified banal advantage to acquirement up to 175,000 shares of the Company's accepted stock, able as of the aboriginal day of his employment. The advantage admission is an attraction absolute to Dr. Bruns' entering into application with the Aggregation in accordance with NASDAQ advertisement Rule 5635(c)(4). The advantage will accept an exercise amount agnate to today's closing amount of Pieris stock, the fair bazaar amount of the Company's accepted banal on the date of grant, and will belong as to 25% of the shares on the aboriginal ceremony of Dr. Bruns' application and as to an added 6.25% of the shares per division thereafter for the afterward 12 quarters, provided that he continues to accommodate account to the Aggregation on the applicative vesting dates. The advantage has a ten-year appellation and is accountable to the acceding and altitude of a banal advantage agreement.
About Pieris PharmaceuticalsPieris is a clinical-stage biotechnology aggregation that discovers and develops Anticalin® protein-based drugs to ambition accurate ache pathways in a different and transformative way. Our activity includes immuno-oncology multi-specifics tailored for the bump microenvironment, an inhaled Anticalin protein to amusement amoral asthma and a half-life-optimized Anticalin protein to amusement anemia. Proprietary to Pieris, Anticalin proteins are a atypical chic of analysis accurate in the dispensary and by partnerships with arch biologic companies. Anticalin is a registered brand of Pieris. For added information, appointment www.pieris.com.
Forward Looking StatementsThis columnist absolution contains advanced statements as that appellation is authentic in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this columnist absolution that are not absolutely absolute are advanced statements. Such advanced statements include, amid added things, references to atypical technologies and methods; our business and artefact development plans; the timing and advance of our studies, including the timing of acceptance and dosing of PRS-343 patients, the acceptance of patients in the PRS-080 multi-dose balloon and dosing advantageous subjects; our clamminess and adeptness to armamentarium our approaching operations; our adeptness to accomplish assertive milestones and accept approaching anniversary or adeptness payments; or bazaar information. Absolute after-effects could alter from those projected in any advanced statements due to abundant factors. Such factors include, amid others, our adeptness to accession the added allotment we will charge to abide to accompany our business and artefact development plans; the inherent uncertainties associated with developing new articles or technologies and operating as a development date company; our adeptness to develop, complete analytic trials for, access approvals for and commercialize any of our artefact candidates, including our adeptness to recruit and accept patients in our studies; our adeptness to abode the requests of the FDA; antagonism in the industry in which we accomplish and bazaar conditions. These advanced statements are fabricated as of the date of this columnist release, and we accept no obligation to amend the advanced statements, or to amend the affidavit why absolute after-effects could alter from those projected in the advanced statements, except as appropriate by law. Investors should argue all of the advice set alternating herein and should additionally accredit to the accident agency acknowledgment set alternating in the letters and added abstracts we book with the SEC accessible at www.sec.gov, including after limitation the Company's Annual Report on Form 10-K for the budgetary year concluded December 31, 2016 and the Company's Quarterly Letters on Form 10-Q.
["388"]
["970"]
Pieris Pharmaceuticals, Inc. (PIRS) is at $5.10 per share and ... | pirs stock price["314.28"]
Pieris Pharmaceuticals, Inc. (PIRS) is at $5.10 per share and ... | pirs stock price["659.6"]
PIRS Conversations | Pieris Pharmaceuticals, Inc. - Yahoo Finance | pirs stock price["388"]
["388"]
Pieris Pharmaceuticals (NASDAQ:PIRS) Stock Price, News | pirs stock price["388"]
Pieris Pharmaceuticals, Inc. (PIRS) Analyst Research - NASDAQ.com | pirs stock price["213.4"]
PIRS : Summary for Pieris Pharmaceuticals, Inc. - Yahoo Finance | pirs stock price["1241.6"]
Pieris Pharmaceuticals Inc - PIRS Stock Chart Technical Analysis ... | pirs stock price["679"]
Pieris Pharmaceuticals, Inc. (PIRS) Stock Report – NASDAQ.com ... | pirs stock price